Findings from University of California, Medical Department provide new insights into menopause

In this recently published study, investigators in the United States conducted a study "To estimate the rates of endometrial hyperplasia, bleeding episodes, and interventions among menopausal women receiving unopposed oral estradiol or placebo therapy with ultrasound monitoring over 3 years. Two-hundred eighteen healthy women with intact uteri enrolled in the Estrogen in the Prevention of Atherosclerosis Trial (EPAT) or the Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial (WELL-HART) were randomly assigned to either 1 mg of micronized 17 beta-estradiol (n=96) or placebo (n=122) daily for up to 3 years in a double-blind fashion."

...

Want to see the full article?

• Purchase this article for only $3.00